Wachovia Cuts Alcon Target

Analyst Theodore Huber says the eye-care company's promising new treatment faces a setback

Wachovia cut the price target for Alcon (ACL ) after its latest eye treatment failed to meet its targets in a clincial study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.